In the last 10 years, the treatment of melanomas improved with the adoption of monoclonal antibodies use, such as Ipilimumab and Pembrolizumab (both PD-1 inhibitors), BRAF inhibitors Dabrafenib and Vemurafenib and Trametinib (MEK inhibitor) [10]. The gene discussed is BRAF; the disease is melanoma.